Sunesis Provides Educational Grant to Support Campaign Sponsor CancerCare
SOUTH SAN FRANCISCO, Calif., Could 25, 2016 (GLOBE NEWSWIRE) — Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced its support for the first-ever Acute Myeloid Leukemia Awareness Month to be held in June. The target of the campaign, which is being sponsored by CancerCare, is to place a spotlight on the disease, a rare and difficult-to-address blood cancer that usually affects older adults.
Acute Myeloid Leukemia (AML) is a cancer of the blood and bone marrow and Can easily worsen promptly if left untreated. According to the National Institutes of Health, it is estimated that there will certainly be 19,950 Brand-new cases of acute myeloid leukemia in 2016 and an estimated 10,430 people will certainly die from the disease. AML is a lot more common in older adults, that are additionally the most difficult to treat, along with 67 as the median age of diagnosis. While progression in treating leukemia has actually been made, there has actually been just one AML treatment approved by the U.S. Meals and Drug Administration in the past 30 years (and that drug was subsequently withdrawn from the market).
Patricia J. Goldsmith
, CEO of CancerCare, said, “AML Awareness Month will certainly feature in-depth post concerning AML on the organization’s website, including a video that features NBA broadcaster Craig Sager
who is battling the disease, also as his son, Craig, Jr., that donated his bone marrow two times in an initiative to save his father. The website will certainly additionally provide people living along with AML and their caregivers easy-to-use, informative resources to know their condition. We thank Sunesis Pharmaceuticals for their unrestricted educational grant which has actually helped to support the improvement of these resources.”
“We are delighted to be supporting CancerCare‘s efforts to enhance awareness of acute myeloid leukemia,” said Daniel Swisher
, Chief Executive Officer of Sunesis. “Due to the fact that it is a rare health problem along with an older patient population, there has actually been little focus focused on AML. As a business that is determined to deliver a Brand-new treatment option for this disease, we wish to support the AML community by assisting to Offer a lot more education and post for patients and caregivers.”
Goldsmith added, “The AML community’s voice has actually not constantly been heard Due to the fact that the health problem itself is so rare and the mortality fee is so high. We chance to place a spotlight on AML in June and suggestions focus focus on the urgent demand these patients and their families have actually for hope.”
Patients and caregivers Can easily discover educational resources on AML online at www.cancercare.org; an unrestricted educational grant from Sunesis has actually helped to support the improvement of the informational resources on AML which additionally involves a patient and caregiver workshop webinar to be held on June 17.
About CancerCare®
Founded in 1944, CancerCare is the leading national organization providing free, professional support services and post to suggestions people regulate the emotional, handy and financial challenges of cancer. Our comprehensive services consist of counseling and support teams over the phone, online and in-person, educational workshops, books and financial and co-payment assistance. every one of CancerCare services are given by oncology social workers and world-leading cancer experts. Headquartered in Brand-new York, NY, CancerCare maintains three extra spots in Norwalk, CT, Ridgewood, NJ and Syosset, NY.
To learn more, visit www.cancercare.org or call 800-813-chance (4673).
About Sunesis Pharmaceuticals
Sunesis is a biopharmaceutical business focused on the improvement and commercialization of Brand-new oncology therapeutics for the potential treatment of tough and hematologic cancers. Sunesis has actually built a highly endured cancer drug improvement organization committed to enhancing the lives of people along with cancer and is currently pursuing regulatory approval in Europe for its lead product candidate, vosaroxin, for the treatment of relapsed or refractory acute myeloid leukemia in patients aged 60 and older. In addition, the business is advancing its kinase-inhibitor pipeline of novel targeted therapies in to the clinic.
For extra post on Sunesis, please visit http://www.sunesis.com.
SUNESIS and the logos are trademarks of Sunesis Pharmaceuticals, Inc.
This press release contains forward-looking statements, including statements related to Sunesis’ corporate objectives, including the anticipated progression and potential approval of vosaroxin by the EMA, potential ex-US partnership, and the expected progression in its kinase inhibitor pipeline. Words such as “prospects,” “look forward,” “potential,” “will” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Sunesis’ current expectations. Forward-looking statements involve risks and uncertainties. Sunesis’ actual outcomes and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, devoid of limitation, the risk that Sunesis Could not have the ability to receive regulatory approval of vosaroxin in the U.S. or Europe, that Sunesis’ improvement tasks for vosaroxin could be otherwise halted or significantly delayed for various reasons, the risk that Sunesis’ clinical studies for vosaroxin or various other product candidates, including its pipeline of kinase inhibitors, Could not demonstrate safety or efficacy or lead to regulatory approval, the risk that data to date and trends Could not be predictive of future data or results, risks related to the conduct of Sunesis’ clinical trials, risks related to Sunesis’ demand for substantial extra funding to finish the improvement and commercialization of vosaroxin and various other product candidates, and risks related to Sunesis’ ability to enhance the capital that it believes to be accessible and is called for to fully finance the improvement and commercialization of vosaroxin and various other product candidates. These and various other risk factors are discussed under “Risk Factors” and elsewhere in Sunesis’ Annual Report on Form 10-K for the year ended December 31, 2015 and Sunesis’ various other filings along with the Securities and Exchange Commission. Sunesis expressly disclaims any sort of obligation or undertaking to release publicly any sort of updates or revisions to any sort of forward-looking statements contained herein to reflect any sort of adjustment in Sunesis’ expectations along with regard thereto or any sort of adjustment in events, conditions or circumstances on which any sort of such statements are based.
Investor and Media Inquiries: David Pitts
Argot Partners 212-600-1902 Eric Bjerkholt Sunesis Pharmaceuticals Inc. 650-266-3717
Source: Sunesis Pharmaceuticals Inc
